Luther King Capital Management (LKCM)’s Vertex Pharmaceuticals VRTX Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-572	Closed	-$201K	–	607
2023 Q2	$201K	Sell	572 -682	-54%	-$230K	﹤0.01%	577
2023 Q1	$395K	Buy	1,254 +6	+0.5%	+$1.8K	﹤0.01%	487
2022 Q4	$360K	Buy	1,248 +31	+3%	+$9.45K	﹤0.01%	494
2022 Q3	$352K	Buy	1,217 +270	+29%	+$77.7K	﹤0.01%	489
2022 Q2	$267K	Buy	+947	New	+$253K	﹤0.01%	557

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Luther King Capital Management (LKCM)'s VRTX Position: Q3 2023 in Review

Luther King Capital Management (LKCM) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 572 shares — an estimated $201K sold.

Luther King Capital Management (LKCM) first reported a position in VRTX in Q2 2022 and held it in 5 quarters. The position peaked at $395K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Luther King Capital Management (LKCM) reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Luther King Capital Management (LKCM) sold 572 Vertex Pharmaceuticals shares in Q3 2023, an estimated $201K.
Luther King Capital Management (LKCM) first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 5 quarters.
Luther King Capital Management (LKCM)'s Vertex Pharmaceuticals position peaked at $395K in Q1 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q3 2023, filed 13 Nov 2023.